Volume 17, Issue 2, Pages (March 2014)

Slides:

Advertisements

Similar presentations

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)— Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication.

Advertisements

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,

Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program Joy Melnikow, MD, MPH, Daniel J. Tancredi, PhD,

Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.

Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants Abhijeet.

Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,

Volume 14, Issue 8, Pages (December 2011)

Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual.

Volume 18, Issue 4, Pages (June 2015)

Volume 18, Issue 5, Pages (July 2015)

Mapping the COPD Assessment Test onto EQ-5D

Volume 15, Issue 2, Pages (March 2012)

Volume 17, Issue 2, Pages (March 2014)

Volume 14, Issue 1, Pages (January 2011)

Volume 18, Issue 4, Pages (June 2015)

Volume 15, Issue 1, Pages S20-S28 (January 2012)

Volume 14, Issue 4, Pages (June 2011)

Volume 17, Issue 8, Pages (December 2014)

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Volume 14, Issue 4, Pages (June 2011)

Volume 15, Issue 6, Pages (September 2012)

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Volume 14, Issue 8, Pages (December 2011)

Multidomain Patient-Reported Outcomes of Irritable Bowel Syndrome: Exploring Person-Centered Perspectives to Better Understand Symptom Severity Scores

Volume 15, Issue 1, Pages (January 2012)

Volume 19, Issue 5, Pages (July 2016)

Volume 15, Issue 2, Pages (March 2012)

Examining the Value of Menopausal Symptom Relief Among US Women

Volume 17, Issue 2, Pages (March 2014)

Value in Health Regional Issues

Eric Nsiah-Boateng, MPH, Moses Aikins, PhD

The Development of the Romanian Scorecard HTA System

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan Kaoru Yamabe, MSc, Puneet K. Singhal,

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

The Process of Privatization of Health Care Provision in Poland

Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F

Ernest Attuquaye Quaye, BPharm, MPH, Edward O

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,

Value in Health Regional Issues

The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems Randall Winnette, MSc, Victor Zárate, MD, MSc,

Omneya Mohamed, PhD, David H. Kreling, PhD

Patient Utility Measurement for Managing Ureteral Stones: A Modified Standard Gamble Approach Ching-Yuan Fann, PhD, Po-Chien Huang, MD, MS, Amy Ming-Fang.

Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M

Value in Health Regional Issues

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Children Hospitalized for Varicella: Complications and Cost Burden

Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project Kyriakos Souliotis, PhD,

Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters? Chun-Ru Chien, MD, PhD, Ya-Chen Tina.

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers Valentina.

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Guidance Document: Global Pharmacoeconomic Model Adaption Strategies

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Colombian Health System on its Way to Improve Allocation Efficiency—Transition from a Health Sector Reform to the Settlement of an HTA Agency Nicolás.

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

The Drug Reimbursement Decision-Making System in Iran

Social Cost of Substance Abuse in Russia

A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina Joaquín.

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.

Speed of Finger Tapping as a Predictor of Functional Outcome After Unilateral Stroke Danielle de Groot-Driessen, MD, Peter van de Sande, MSc, Caroline.

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Volume 17, Issue 2, Pages 245-253 (March 2014) Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib? Margreet G. Franken, MSc, Jennifer G. Gaultney, MPH, MSc, Hedwig M. Blommestein, MSc, Peter C. Huijgens, PhD, MD, Pieter Sonneveld, PhD, MD, William K. Redekop, PhD, Carin A. Uyl-de Groot, PhD Value in Health Volume 17, Issue 2, Pages 245-253 (March 2014) DOI: 10.1016/j.jval.2013.12.009 Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Flowchart of the patient selection process. Value in Health 2014 17, 245-253DOI: (10.1016/j.jval.2013.12.009) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Kaplan-Meier OS curves from start of relapsed/refractory treatment stratified by treatment with bortezomib. Value in Health 2014 17, 245-253DOI: (10.1016/j.jval.2013.12.009) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Kaplan-Meier OS curves from start of relapsed/refractory treatment stratified by treatment with bortezomib, bortezomib treatment line and Hovon50 treatment arm. Value in Health 2014 17, 245-253DOI: (10.1016/j.jval.2013.12.009) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions